Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1204320090250030219
Laboratory Animal Research
2009 Volume.25 No. 3 p.219 ~ p.224
Comparison of Intravenous versus Intranasal Administrations in Effectiveness of Ondansetron on Cisplatin-Induced Emesis in Ferrets
Jang Dong-Hyok

Sung Ha-Jung
Han Won-Jun
Kim Yang-Joong
Yoon Sang-Yeoung
Kim Sang-Yong
Jeong Jae-Hwang
Hue Jin-Joo
Nam Sang-Yoon
Yun Young-Won
Lee Beom-Jun
Kim Jong-Soo
Abstract
This study was carried out to assess the potential of intranasal administration of ondansetron (a 5-HT©ý receptor antagonist, which antagonize the acute emetic response) in preventing cisplatin-induced emesis in the ferret. After intranasal administration of ondansetron at doses of 0.3 and 0.6 §·/§¸, the peak plasma concentrations (Cmax) were 38 and 66.7 ng/mL, and attained at 13 and 23 min (Tmax) respectively. The intravenous (0.3 §·/§¸) and intranasal (0.6 §·/§¸) administrations of ondansetron significantly delayed the latency time to the first retching and vomiting. In acute phase of emesis during 24 hr, the number of vomits and retches were significantly reduced both in intravenous and intranasal administration groups. In delayed emesis (24-72 hr), intranasal administration of ondansetron at a higher dose of 0.6 §·/§¸ or intravenous injection of 0.3 §·/§¸ significantly reduced retching but not vomiting. Intranasal ondansetron, administered as 0.6 §·/§¸ dose, provided potency in antiemetic control comparable to intravenous ondansetron (0.3 §·/§¸) in cisplatin-induced acute emesis, without well known side effects when injected via intravenously. These results suggest that intranasal administration of ondansetron can be an effective substitute for intravenous administration for the prevention of cisplatin-induced acute emesis.
KEYWORD
Cisplatin, ondansetron, emesis, vomit, retch, ferret, intranasal administration
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed